Montreal — Every day, our gut comes in contact with bacteria, inducing a basal inflammatory response that is tolerated and highly controlled. However, in some cases the control of inflammation is lost and this can lead to inflammatory bowel disease that may predispose to colon cancer. Caspase-1, an important protein involved in the mechanism of inflammation, has long been believed to be one of the culprits behind excessive inflammation in the colon. Dr. Maya Saleh, a researcher at the MUHC Research Institute, and her colleagues suggest the opposite in their new study.
The MUHC/McGill researchers have demonstrated that Caspase-1 plays a crucial role in inflammation regulation and intestinal tissue repair. But too much of any good thing can sometimes be bad. They also demonstrated that if Caspase-12–the protein that blocks Caspase-1–is absent, the inflammation mechanism caused by Caspase-1 goes out of control. Their findings, which were published in the journal Immunity, open the door to a greater understanding of and more targeted treatment strategy for preventing diseases linked to inflammation of the intestine as well as certain cancers.
This discovery is of major interest from the therapeutic point of view because many pharmaceutical companies have developed Caspase-1 inhibitors since the late 1990s with the goal of relieving the symptoms of colitis. However, Dr. Saleh’s team observed that inhibition or deletion of Caspase-1 was not protective and actually caused an intense inflammatory reaction that led to severe colitis.
“Caspase-1 is needed to maintain the intestinal barrier and to repair it if injured. It works by stimulating the cells that line the intestinal barrier to proliferate and fill the site of damage or ulcer. This barrier shields us from the bacteria that colonize our gut,” explains Dr. Saleh. “Without it, these bacteria invade to deeper tissues and trigger a persistent inflammation.”
According to Dr. Saleh, the absence of Caspase-12 leads to uncontrolled cell proliferation and higher risk of colorectal cancer. “If Caspase-1 is not eventually blocked, it could lead to appearance of tumours,” she says.
“Our challenge at present is to further our research on the action of Caspases in the immune response and also to see whether they play a role in other types of cancer.”
Dr. Maya Saleh is a researcher in the Division of Intensive Care at the Research Institute of the McGill University Health Centre (MUHC), and an Assistant Professor in the Faculty of Medicine, McGill University.
About the Study
The article “Control of Intestinal Homeostasis, Colitis, and Colitis-Associated Colorectal Cancer by the Inflammatory Caspases,” published in the journal Immunity, was authored by Jeremy Dupaul-Chicoine, Garabet Yeretssian, Karine Doiron, Philippe M. LeBlanc, Christian R. McIntire, and Maya Saleh from the RI MUHC and McGill University, Charles Meunier, Claire Turbide, Nicole Beauchemin and Philippe Gros, from McGill University and Kirk S.B. Bergstrom and Bruce A. Vallance from the University of British Columbia and BC Children’s Hospital.
This study was made possible by grants from the Canadian Institutes of Health Research, the Burroughs Wellcome Foundation, the CHILD Foundation and the Canadian Society for Immunology.